Kyntra Bio (KYNB) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 12, 2026, with voting on director election, executive compensation, and auditor ratification.

• The company underwent a major transformation in 2025, including a business reset, sale of international operations, and workforce reduction.

• Proxy materials are available online, and shareholders are encouraged to vote electronically or by mail.

Voting matters and shareholder proposals

• Shareholders will vote to elect Michael Kauffman, M.D., Ph.D., as Class III director until 2029.

• Advisory vote on executive compensation (say-on-pay) is included.

• Ratification of PricewaterhouseCoopers LLP as independent auditor for 2026 is on the agenda.

• Shareholder proposals for the 2027 meeting are due by December 28, 2026.

Board of directors and corporate governance

• The board consists of five members, with a majority being independent under Nasdaq and SEC rules.

• Board leadership is separated, with an independent chairperson.

• Committees include Audit, Compensation, and Nominating and Corporate Governance, all composed of independent directors.

• Board diversity: 20% female, 20% Asian; 50% of U.S. workforce is female, 50% Asian, Hispanic, or Black.